bispecific cancer
Bristol Myers Terminates Partnership with Immatics on Bispecific Cancer Drug After $150M Investment
Bristol Myers Squibb, Immatics, bispecific cancer drug, partnership termination, $150M investment
Actionable Insights Powered by AI
Bristol Myers Squibb, Immatics, bispecific cancer drug, partnership termination, $150M investment